Multivariate Cox proportional hazard regression analysis of driver mutations (JAK2, CALR, and MPL) and IPSS variables evaluated as risk factors for survival in patients with PMF
| Covariates . | HR . | 95% CI . | P . |
|---|---|---|---|
| Driver mutation (JAK2, CALR, and MPL mutation status) | |||
| CALR exon 9 indel* | 1 | ||
| JAK2 (V617F) | 1.9 | 1.2-3.0 | .004 |
| MPL exon 10 mutation | 2.7 | 1.3-5.6 | .009 |
| Nonmutated JAK2, CALR, and MPL | 2.6 | 1.4-4.6 | .002 |
| IPSS variables | |||
| Age >65 y | 3.5 | 2.5-4.9 | <.001 |
| WBC count >25 × 109/L | 3.4 | 2.2-5.2 | <.001 |
| Hemoglobin <10 g/dL | 2.0 | 1.4-2.9 | <.001 |
| Peripheral blood blasts ≥1% | 2.0 | 1.4-2.8 | <.001 |
| Presence of constitutional symptoms | 1.9 | 1.4-2.6 | <.001 |
| Covariates . | HR . | 95% CI . | P . |
|---|---|---|---|
| Driver mutation (JAK2, CALR, and MPL mutation status) | |||
| CALR exon 9 indel* | 1 | ||
| JAK2 (V617F) | 1.9 | 1.2-3.0 | .004 |
| MPL exon 10 mutation | 2.7 | 1.3-5.6 | .009 |
| Nonmutated JAK2, CALR, and MPL | 2.6 | 1.4-4.6 | .002 |
| IPSS variables | |||
| Age >65 y | 3.5 | 2.5-4.9 | <.001 |
| WBC count >25 × 109/L | 3.4 | 2.2-5.2 | <.001 |
| Hemoglobin <10 g/dL | 2.0 | 1.4-2.9 | <.001 |
| Peripheral blood blasts ≥1% | 2.0 | 1.4-2.8 | <.001 |
| Presence of constitutional symptoms | 1.9 | 1.4-2.6 | <.001 |
Reference category.